The observed changes in CEA and CA19-9 values provide new insights to guide clinicians during evaluation of the complex tumor-specific response to NACT in LAGC patients, and are expected to inform future selection of the optimal therapeutic strategy. This evidence concerns the gene CEACAM5 and neoplasm.